Dr. Pegram on Developing Agents for Patients With HER2+ Breast Cancer and Brain Metastases

Video

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses developing agents for patients with HER2-positive breast cancer who have brain metastases.

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses developing agents for patients with HER2-positive breast cancer who have brain metastases.

Nancy U. Lin, MD, showed a paper at the 2017 ASCO Annual Meeting looking at high doses of trastuzumab (Herceptin) after passing the first step of a Simon’s Two-Stage design. The 40-patient, randomized phase II PATRICIA trial has completed enrollment and results are pending. There are also new small-molecule HER2-targeted agents that are more specific to HER2. They don’t show as much toxicity as other drugs, such as lapatinib (Tykerb) or neratinib (Nerlynx).

Tucatinib (ONT-380) is a pure HER2-directed therapy that doesn’t inhibit EGFR. It doesn’t result in diarrhea and skin rash to the extent of existing FDA-approved HER2-targeted agents. That molecule is in an ongoing randomized registration trial. Additionally, recently published data on FDA-approved trastuzumab emtansine (TDM-1; Kadcyla) show anecdotal responses and high tolerability.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute